Renexxion holders would own about 72.2% of the combined company under the initial ratio. The companies aim to sign a definitive agreement by December 31, 2024.
Latest MindMaze Therapeutics Holding SA news
We have not published a story on MindMaze Therapeutics Holding SA yet. When there is news, it will appear here.
MindMaze Therapeutics Holding SA annual financials
Latest balance sheet, Dec 31, 2023 (20-F): cash and equivalents CHF 14.6 million.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about MindMaze Therapeutics Holding SA
Is MindMaze Therapeutics Holding SA doing a reverse merger?
Our latest story on this, dated Nov 5, 2024: "Relief Therapeutics (now MindMaze) signs non-binding LOI for Renexxion reverse merger". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of MindMaze Therapeutics Holding SA?
MindMaze Therapeutics Holding SA trades under the ticker MMTX on SIX.
Where is MindMaze Therapeutics Holding SA listed?
MindMaze Therapeutics Holding SA is listed on SIX. Our directory also records these other listings: GETTEX:V6M; LS:A3EFB5; LSE:0QKQ; OTC:MMTZF.
What is the SEC CIK of MindMaze Therapeutics Holding SA?
The SEC Central Index Key (CIK) for MindMaze Therapeutics Holding SA is 1854078. Its filings are on SEC EDGAR.
How many shares does MindMaze Therapeutics Holding SA have outstanding?
12,540,439 shares as of 2023-12-31, per the cover page of its 20-F filed 2024-04-30.
Which country or territory is MindMaze Therapeutics Holding SA listed under?
Our directory records MindMaze Therapeutics Holding SA under Switzerland.
What does MindMaze Therapeutics Holding SA do?
Our directory classifies MindMaze Therapeutics Holding SA as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of MindMaze Therapeutics Holding SA?
The ISIN recorded for MindMaze Therapeutics Holding SA is CH1251125998.
Does aibio.space cover MindMaze Therapeutics Holding SA?
aibio.space lists MindMaze Therapeutics Holding SA among 2,820 public biotech companies and publishes its news here as stories appear.
Where is MindMaze Therapeutics Holding SA incorporated?
SEC records list its state or country of incorporation as V8.
What is the latest MindMaze Therapeutics Holding SA (MMTX) stock news?
Our latest story on MindMaze Therapeutics Holding SA, dated Nov 5, 2024: "Relief Therapeutics (now MindMaze) signs non-binding LOI for Renexxion reverse merger". Renexxion holders would own about 72.2% of the combined company under the initial ratio. The companies aim to sign a definitive agreement by December 31, 2024. Source.
Is MindMaze Therapeutics Holding SA a smaller reporting company?
SEC records list MindMaze Therapeutics Holding SA's filer category as: Non-accelerated filer<br>Emerging growth company.
Where is MindMaze Therapeutics Holding SA headquartered?
SEC records list its business address as AVENUE DE SECHERON 15, CH-1202 GENEVA.
When does MindMaze Therapeutics Holding SA's fiscal year end?
MindMaze Therapeutics Holding SA's fiscal year ends on December 31, per SEC records.
What did MindMaze Therapeutics Holding SA last file with the SEC?
Its most recent filing in our record is a 6-K filed 2024-12-16. All of its filings are on SEC EDGAR. Source.
Investor discussion: MindMaze Therapeutics Holding SA
Members talk about MindMaze Therapeutics Holding SA (MMTX). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at MindMaze Therapeutics Holding SA, newest first. Each line links the filing it comes from.
Mergers
Reported a merger or acquisition agreement. SEC Form 6-K. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open SIX:MMTX on TradingView.
SEC filings and registration
SEC name
MindMaze Therapeutics Holding SA
CIK
1854078
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
MMTZF (OTC), RLFTY (OTC)
State or country of incorporation
V8
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Emerging growth company
Business address
AVENUE DE SECHERON 15, CH-1202 GENEVA
Phone
914-672-3555
Shares outstanding
12,540,439 as of 2023-12-31 (20-F filed 2024-04-30)
Former names
Relief Therapeutics Holding SA; Relief Therapeutics Holding AG
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
MindMaze Therapeutics Holding SA is a public biotech or pharmaceutical company listed on SIX under the ticker MMTX, recorded under Switzerland. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio